Twist Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on November 22, 2021, reporting events occurring on November 19, 2021. Twist Bioscience Corporation (TWST) entered into a definitive Merger Agreement to acquire AbX Biologics, Inc. (d/b/a Abveris), a biopharmaceutical company.
Key Financial Metrics and Transaction Details
The filing details a strategic acquisition rather than routine financial performance metrics. The total purchase consideration for the acquisition of Abveris is up to $190 million, structured as follows:
- Closing Consideration: Up to $150 million, consisting of Twist Common Stock (valued at a price between $106.10 and $129.68 per share) and up to $10 million in cash.
- Contingent Consideration: Up to $40 million in Twist Common Stock, payable if Abveris achieves an internal revenue target for calendar year 2022.
- Adjustments: Consideration is subject to customary adjustments for cash, net working capital, outstanding indebtedness, and unpaid transaction expenses.
The filing does not provide specific revenue, profit, cash flow, or debt figures for Twist Bioscience for the reporting period.
Material Changes
The primary material change is the execution of the Merger Agreement to acquire Abveris, intended to bolster Twist's biopharma capabilities. The shares of Twist Common Stock to be issued in this transaction are unregistered and will be issued in reliance on exemptions under Section 4(a)(2) and/or Rule 506 of Regulation D.
Outlook, Risks, and Contingencies
Contingencies: A portion of the deal value ($40 million) is contingent on Abveris meeting a specific internal revenue target in 2022. The final stock consideration is subject to a pricing formula based on the 30-day average closing price prior to closing, with a floor of $106.10 and a cap of $129.68 per share.
Risks: The transaction is subject to customary closing conditions. The unregistered nature of the stock issuance limits its immediate tradability in the U.S. absent registration or an applicable exemption.
Key Facts for Investor Verification
- Verify the final purchase price per share of Twist stock at closing to determine the exact equity dilution.
- Confirm the specific internal revenue target Abveris must meet to trigger the $40 million contingent payment.
- Review the definitive Merger Agreement (Exhibit 99.1 referenced in the filing) for detailed closing conditions and indemnification terms.
- Monitor future filings for the registration status of the shares issued to Abveris shareholders.